# ABBOTT LABORATORIES (ABT) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from ABBOTT LABORATORIES's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ABT/mda/fy2025/): filed 2026-02-20; accession 0001628280-26-010185 (https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/ABT/mda/fy2024/): filed 2025-02-21; accession 0001628280-25-007110 (https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/abt-20241231.htm)
- [FY 2023 MD&A](/company/ABT/mda/fy2023/): filed 2024-02-16; accession 0001628280-24-005348 (https://www.sec.gov/Archives/edgar/data/1800/000162828024005348/abt-20231231.htm)
- [FY 2022 MD&A](/company/ABT/mda/fy2022/): filed 2023-02-17; accession 0001628280-23-004026 (https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/abt-20221231.htm)
- [FY 2021 MD&A](/company/ABT/mda/fy2021/): filed 2022-02-18; accession 0001104659-22-025141 (https://www.sec.gov/Archives/edgar/data/1800/000110465922025141/abt-20211231x10k.htm)

Back to /company/ABT/